InvestorsHub Logo
Followers 45
Posts 9498
Boards Moderated 0
Alias Born 07/14/2005

Re: govorchin post# 58857

Thursday, 04/24/2014 6:36:02 PM

Thursday, April 24, 2014 6:36:02 PM

Post# of 402178
Thanks gov!

Here is a link to CBST's (Cubist Pharma) financials:

https://ca.finance.yahoo.com/q/ks?s=CBST

They have over $500 million in cash and $1 billion in revenue (most of it from Daptomyacin).

Their Market Cap is about $5 billion,... with about 75 million shares outstanding, trading at $66.51,... with a high of over $80 this year.

I can see them taking an interest in purchasing B (ABSSSI) from CTIX. They have the cash and also the distribution network in place for serious Anti-Biotic medicines.

They are also situated in Lexington, Massachusetts... not too far from us.

They might also be interested in the drugs CTIX is doing INVIVO testing for at that Texas University.

In a thigh burden study of a multi-drug resistant strain of Klebsiella pneumoniae in a mouse model, Cellceutix’s defensin mimetic compound CTIX1278, was efficacious as compared to a carbapenem antibiotic that is widely used as a last line of defense against drug-resistant, Gram-negative bacteria, including Klebsiella pneumoniae. A second study is now being conducted at multiple dosing levels with various infusion parameters with the goal of increasing efficacy and further defining a treatment protocol for the compound.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent IPIX News